Clinical and radiological criteria for candidate patients with small bowel neuroendocrine neoplasms (SB-NEN) for minimally invasive surgery: A single-centre experience.

Authors

null

Lorenzo Guidi

Istituto Europeo di Oncologia IRCCS, Milano, Italy

Lorenzo Guidi , Guglielmo Conti , Alessandro Michele Bonomi , Francesca Spada , Lorenzo Gervaso , Chiara Alessandra Cella , Emilio Bertani , Fabio Zugni , Lavinia Benini , Michele Borghesani , Laura Algeri , Giuseppe Curigliano , Luigi Funicelli , Uberto Fumagalli Romario , Nicola Fazio

Organizations

Istituto Europeo di Oncologia IRCCS, Milano, Italy, European Institute of Oncology, Milan, Italy, European Institute of Oncology, IEO, IRCCS, Milan, Italy, European Institute of Oncology (IEO) IRCCS, Milan, Italy, Istituto Europeo Oncologico, Milano, MI, Italy, IEO, European Institute of Oncology IRCCS, Milan, Milano, Italy, Istituto Europeo Oncologico, Milano, Italy, European Institute of Oncology - IRCCS, Milan, Italy

Research Funding

No funding received
None.

Background: Although open resection represents the standard of care of localized small bowel neuroendocrine neoplasms (SB-NEN), minimally invasive surgery (MIS) has proven to be a viable alternative in patients with low disease burden. This study aims to assess the reliability of preoperative clinical and radiological criteria used at European Institute of Oncology (IEO) to candidate patients with SI-NEN to MIS. Methods: Patients diagnosed with SB-NEN and eligible for MIS at IEO were retrospectively evaluated between 2013 and 2022. Preoperative physical examination, CT enterography (CTE) and Ga68-DOTATOC-PET-CT were used for clinical staging. At IEO NEN multidisciplinary tumor board, the following eligibility criteria were adopted to candidate patients to MIS (curative or palliative): number and localization of primary tumor, grade of superior mesentery artery and vein encasement by lymph-node metastases of 0-2 according IEO criteria (based on Lardiere-Degalte classification). Information on morphology and carcinoid syndrome were collected. The primary endpoint was laparotomy conversion rate. Results: Twelve patients were selected. Patients’ characteristics are available. Median age at surgery was 55 years (range: 33–73). Among these patients, based on pathological findings, 8 (67%) had confirmed nodal involvement, 3 (25%) metastatic disease and 4 (33%) multifocal primary tumor. Vascular involvement (based on IEO criteria) was found in 9 patients (75%). Of note, only 3 (25%) patients had a functioning tumor as a preoperative finding and all tumors resulted well-differentiated. Among 12 patients which underwent laparoscopic surgery, none has been converted to laparotomy surgery. After a median follow-up of 25.3 months (range: 2.5-71.3), the 1-year disease free survival for non-metastatic patients was of 100%. Conclusions: the assessment of tumor burden with 68Ga-PET-CT and CTE according to IEO criteria could be a reliable method to candidate patients affected by SB-NEN to MIS, according to a multidisciplinary approach.

Patient characteristics.

Preoperative findings, A
(N=12)
Intraoperative findings, B
(N=12)
Pathological findings, C
(N=12)
cN0 cM0 disease – n. (%)3 (25%)NA1 (8%)
cN+ cM0 disease – n. (%)6 (50%)NA8 (67%)
cM+ disease – n. (%)3 (25%)NA3 (25%)
Multifocal primary tumor – n. (%)3 (25%)3 (25%)4 (33%)
Type of surgery
Ileal resection – n. (%)NANA6 (50%)
Right emicolectomy – n. (%)NANA6 (50%)
Vascular involvement (IEO Criteria)
SMA involvement 0/1/2 – n. (%)3/7/2 (25/58/17 %)NANA

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e16246)

DOI

10.1200/JCO.2023.41.16_suppl.e16246

Abstract #

e16246

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Breakthrough

The safety of robot-assisted surgery versus laparoscopic surgery for rectal tumor patients.

First Author: Jesse Yu Tajima

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Advantages of minimally invasive surgery for remnant gastric cancer: A multi-institutional cohort study.

First Author: Ryuhei Aoyama

First Author: Laynara Vitória Da Silva Vieira